Biogen 주식 가격. 1BIIB - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

105.80

매수가

104.05

매도가

106.60

거래량

105.80 일간 변동폭 105.80

103.00 52주 범위 220.70

market_cap

15.486B

전일 종가

105.30

개장가

105.80

최근 거래 시간

105.8

마지막 거래 시간

20:03:18

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

146,374,937

배당수익률

주가수익률

10.72

주당순이익(EPS)

11.15

매출

9.68B

순이익

1.63B

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.biogen.com

본부

Wilmington, Delaware, USA

설립됨

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the 이탈리아 증권거래소 with ticker 1BIIB. The last closing price for Biogen was 105.30 €. Over the last year, Biogen shares have traded in a share price range of 103.00 € to 220.70 €.

Biogen currently has 146,374,937 shares in issue. The market capitalisation of Biogen is 15.41 € billion. Biogen has a price to earnings ratio (PE ratio) of 10.72.

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union In the...

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease CAMBRIDGE...

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square Biogen signs lease for Kendall Common as part of...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients Global...

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare...

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE...

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Once every four weeks maintenance...

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA Applications are based on data from the DEVOTE study, which...

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	2.3	2.22222222222	103.5	107.35	103.5	50	104.88013245	DE
4	-20.6	-16.2974683544	126.4	126.5	103	30	111.0752551	DE
12	-35.4	-25.0708215297	141.2	145.05	103	53	130.36759003	DE
26	-64.6	-37.9107981221	170.4	173.4	103	53	139.49594649	DE
52	-83.35	-44.0655564367	189.15	220.7	103	46	155.0651107	DE
156	-109.8	-50.9276437848	215.6	244.6	103	42	163.73556719	DE
260	-109.8	-50.9276437848	215.6	244.6	103	42	163.73556719	DE

1BIIB - Frequently Asked Questions (FAQ)

What is the current Biogen share price?

The current share price of Biogen is 105.80 €

How many Biogen shares are in issue?

Biogen has 146,374,937 shares in issue

What is the market cap of Biogen?

The market capitalisation of Biogen is EUR 15.41B

What is the 1 year trading range for Biogen share price?

Biogen has traded in the range of 103.00 € to 220.70 € during the past year

What is the PE ratio of Biogen?

The price to earnings ratio of Biogen is 10.72

What is the cash to sales ratio of Biogen?

The cash to sales ratio of Biogen is 1.81

What is the reporting currency for Biogen?

Biogen reports financial results in USD

What is the latest annual turnover for Biogen?

The latest annual turnover of Biogen is USD 9.68B

What is the latest annual profit for Biogen?

The latest annual profit of Biogen is USD 1.63B

What is the registered address of Biogen?

The registered address for Biogen is 3411 SILVERSIDE ROAD TATNALL, BUILDING #104, NEW CASTLE, WILMINGTON, DELAWARE, 19810

What is the Biogen website address?

The website address for Biogen is www.biogen.com

Which industry sector does Biogen operate in?

Biogen operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
BESBestbe Holding	0.1869 € (25.69%)	90.38k
SCKSciuker Frames SpA	0.88 € (15.49%)	14.1k
RDUEErreDue SpA	8.35 € (12.08%)	20.8k
SGFSogefi Spa	2.035 € (9.29%)	789.79k
IMDIMD International Medical Devices SpA	1.52 € (8.57%)	4.5k
1FISVFiserv Inc Dl 01	157.00 € (-18.55%)	35
1AURAurubis AG	65.20 € (-13.93%)	5
WLS26Lemon Sistemi SpA	0.0606 € (-13.68%)	6.9k
1DASHDoorDash Inc	142.64 € (-10.54%)	7
FDAFidia	0.0038 € (-7.32%)	41.59M
TITTelecom Italia SpA	0.3409 € (0.89%)	123.65M
FDAFidia	0.0038 € (-7.32%)	41.59M
SPMSaipem Spa	1.9795 € (0.79%)	26.81M
ISPIntesa Sanpaolo Spa	4.6165 € (1.29%)	17.5M
BMPSBanca Monte Dei Paschi Di Siena Spa	7.106 € (3.27%)	10.29M